Listen on the go
CORRECT!
Next question
touchDERMATOLOGY touchDERMATOLOGY

Start Learning

Touch Loading image
Early-onset atopic dermatitis
JOURNALS
Start Learning
Specific cord-blood DNA methylation patterns associated with risk of early-onset atopic dermatitis
touchEXPERT OPINIONS
Start Learning
Navigating treatment choices in high-risk early-stage melanoma
CE/CME ACCREDITED
JOURNALS
Start Learning
Ruxolitinib cream shows safe and lasting control in paediatric atopic dermatitis
touchMEETING HIGHLIGHTS
Start Learning
ADVENT symposia 2024: Updates in AD, PN and CSU
Sponsored content
JOURNALS
Start Learning
Breaking new ground in CSU treatment: Highlights from EAACI 2024
CONFERENCE HUB
Start Learning
Barzolvolimab shows sustained efficacy over 52 weeks in antihistamine-refractory chronic spontaneous urticaria
touchEXPERT BRIEFING
Start Learning
Advances in the treatment of CSU
Sponsored content
David Rosmarin: Tapinarof 1% in atopic dermatitis: Can patients take a drug holiday and maintain response?
CONFERENCE HUB
Start Learning
Tapinarof 1% in atopic dermatitis: Can patients take a drug holiday and maintain response?
journal placeholder
JOURNALS
Start Learning
Dr Ben Kaffenberger joins Expert Faculty: Specialist in complex skin conditions
JOURNALS
Start Learning
Honouring Prof. Marcus Maurer

to view Favourites, Keep Notes and Track CME Credits

Favourites
Navigating the management of cholestatic pruritus in patients with PBC: Insights from the multidisciplinary team
View
Encouraging results for topical 1.5% ruxolitinib cream in milder cases of hidradenitis suppurativa
View
Breaking new ground in CSU treatment: Highlights from EAACI 2024
View
Ruxolitinib cream shows safe and lasting control in paediatric atopic dermatitis
View
Tapinarof 1% in atopic dermatitis: Can patients take a drug holiday and maintain response?
View
Pooled phase III data reinforce dupilumab’s efficacy in H1-antihistamine refractory chronic spontaneous urticaria
View
Introducing our newest Expert Faculty member: A leader in urticaria, drug allergies and angioedema
View
Treating moderate-to-severe atopic dermatitis in children and adolescents: Insights from the experts
View
Novel, oral TYK2 inhibitor, ESK-001, reports improved efficacy with prolonged use in plaque psoriasis
View
Breakthroughs in melanoma: Highlights from ASCO 2024
View
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup